Intuitive Surgical, Inc. (NASDAQ:ISRG) is Waycross Partners LLC’s 8th Largest Position

Waycross Partners LLC cut its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.6% in the 4th quarter, Holdings Channel reports. The firm owned 52,349 shares of the medical equipment provider’s stock after selling 3,094 shares during the period. Intuitive Surgical makes up about 3.3% of Waycross Partners LLC’s portfolio, making the stock its 8th biggest position. Waycross Partners LLC’s holdings in Intuitive Surgical were worth $17,660,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of ISRG. WCM Investment Management LLC bought a new position in shares of Intuitive Surgical in the 4th quarter worth about $575,536,000. International Assets Investment Management LLC increased its stake in shares of Intuitive Surgical by 32,360.5% during the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after purchasing an additional 684,749 shares in the last quarter. Alphinity Investment Management Pty Ltd lifted its holdings in shares of Intuitive Surgical by 113.2% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after purchasing an additional 677,455 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new stake in shares of Intuitive Surgical in the 3rd quarter worth approximately $178,667,000. Finally, Quadrature Capital Ltd grew its stake in shares of Intuitive Surgical by 466.2% in the 3rd quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after buying an additional 280,480 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Down 0.9 %

NASDAQ:ISRG traded down $3.52 on Tuesday, hitting $370.62. The stock had a trading volume of 1,212,524 shares, compared to its average volume of 1,644,877. The business’s 50-day simple moving average is $385.96 and its two-hundred day simple moving average is $348.19. The stock has a market cap of $131.46 billion, a price-to-earnings ratio of 66.90, a price-to-earnings-growth ratio of 4.85 and a beta of 1.36. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.00 EPS. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several analyst reports. Truist Financial boosted their target price on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Mizuho lifted their target price on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Barclays upped their target price on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Stifel Nicolaus raised their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Finally, Raymond James upped their price objective on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and an average price target of $396.17.

Insiders Place Their Bets

In related news, EVP Robert Desantis sold 376 shares of Intuitive Surgical stock in a transaction on Monday, April 29th. The stock was sold at an average price of $375.39, for a total transaction of $141,146.64. Following the transaction, the executive vice president now directly owns 5,507 shares in the company, valued at $2,067,272.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $375.39, for a total transaction of $141,146.64. Following the sale, the executive vice president now owns 5,507 shares in the company, valued at $2,067,272.73. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 226,967 shares of company stock worth $87,848,586. Company insiders own 0.80% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.